Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24786481 | 0.80 | BRD4 (0.35) | BRD4LCKGAAMETAP2KDM4E | |
| SCHEMBL20577534 | 0.78 | AXL (0.37) | BRD4LCKGAAMETAP2KDM4E | |
| SCHEMBL21725762 | 0.76 | BRD4 (0.33) | BRD4LCKGAAMETAP2KDM4E | |
| SCHEMBL25241637 | 0.72 | AXL (0.37) | BRD4LCKGAAMETAP2KDM4E | |
| SCHEMBL26077705 | 0.71 | METAP2 (0.33) | BRD4METAP2 | |
| SCHEMBL29285140 | 0.70 | LMNA (0.40) | BRD4LCKMETAP2KDM4EALDH1A1 | |
| SCHEMBL20577587 | 0.70 | EGFR (0.33) | — | |
| SCHEMBL24274223 | 0.66 | AXL (0.41) | BRD4LCKMETAP2 | |
| SCHEMBL29474160 | 0.66 | AXL (0.41) | BRD4LCKMETAP2 | |
| SCHEMBL21196014 | 0.65 | HTT (0.35) | BRD4LCKGAAMETAP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | BRD4 4666/4885LCK 1038/4885GAA 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.